Yokota, Tomoya <br/><br/>
Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer.  [electronic resource] 

 -  Anticancer research  Oct 2011 
 - 3535-41 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1791-7530 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Cisplatin--adverse effects<br/>Disease-Free Survival<br/>Docetaxel<br/>Esophageal Neoplasms--drug therapy<br/>Female<br/>Fluorouracil--adverse effects<br/>Humans<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Postoperative Complications--etiology<br/>Recurrence<br/>Retrospective Studies<br/>Taxoids--adverse effects<br/>Treatment Outcome